Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives ...

Merck last year signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's experimental oral drug to ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set ...

Most recently, Danish drugmaker Novo Nordisk bought global rights to China-based United Laboratories International's weight-loss drug candidate in a deal worth up to $2 billion. Merck last year ...

bought global rights to China-based United Laboratories International’s weight-loss drug candidate in a deal worth up to $2 billion. Merck last year signed a licensing deal worth up to $2 ...

This year's two sessions is a reconfirmation of the confidence that Merck has in China because the Chinese government has set the economic growth target at 5 percent, focusing more on innovation ...

Merck (NYSE:MRK) is doubling down on China's biotech boomthis time with a $2 billion licensing deal for a potential blockbuster heart drug from Jiangsu Hengrui Pharmaceuticals. The deal gives Merck ...

the latest in a series of deals U.S. drugmakers have recently signed with China-based firms. Large drugmakers including Merck and Eli Lilly (LLY.N), opens new tab have turned to Chinese biotechs ...

Merck & Co. is leveraging March 4’s International HPV Awareness Day for a marketing campaign in China, lighting up landmark buildings in four megacities in the hopes of reigniting demand amid ...

He was also upbeat about a Chinese program to encourage American college students to visit China. And yet, Chen noted, the White House referred to China as an “adversary” last month in a ...

The moves in China by the likes of Merck also come as the industry stares down a wave of generic drugs this year that has made the issue of securing new candidates all the more pressing.